Articles

O.2 Nanobodies as new imaging tools in multiple myeloma: a study in the 5T2MM murine model

BJH - 2013, issue BHS Abstractbook, january 2013

M. Lemaire , S. Muyldermans , T. Lahoutte , M. Menu , E. Van Valckenborgh PhD, E. De Bruyne , N. Devoogdt , K. Vanderkerken PhD

Read more

P.05 The Combination of Decitabine and the Histone Deacetylase Inhibitor JNJ-26481585 Has Synergistic Anti-Myeloma Activity

BJH - 2013, issue BHS Abstractbook, january 2013

dr. K. Maes , M. Lemaire , E. De Smedt , E. Menu , E. Van Valckenborgh PhD, K. Vanderkerken PhD, E. De Bruyne

Read more

P.27 Invariant Natural Killer T cells in the 5T33 multiple myeloma model

BJH - 2013, issue BHS Abstractbook, january 2013

H. Nur , K. Fostier MD, S. Aspeslagh , W. Renmans , E. Bertrand , X. Leleu , K. Breckpot , R. Schots MD, PhD, M. De Waele , E. Van Valckenborgh PhD, E. De Bruyne , T. Facon , D. Elewaut , K. Vanderkerken PhD, E. Menu

Read more

P.28 The IGF-1 receptor inhibitor picropodophyllin (PPP) potentiates the anti-myeloma effects of the BH3 mimetic ABT-737

BJH - 2013, issue BHS Abstractbook, january 2013

L. Bieghs , E. Van Valckenborgh PhD, E. Menu , M.T. Overgaard , M. Nyegaard , H. Johnsen , O. Larsson , H. Jernberg-Wiklund , K. Vanderkerken PhD, E. De Bruyne

Read more

P.32 The generation and activation of Myeloid-Derived Suppressor Cells in Multiple Myeloma

BJH - 2013, issue BHS Abstractbook, january 2013

K. De Veirman , E. De Bruyne , E. Menu , I. Van Riet PhD, K. Vanderkerken PhD, E. Van Valckenborgh PhD

Read more